Novartis
NVSVerifiedNVS · Stock Price
Historical price data
Overview
Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.
Technology Platform
A diversified portfolio of six integrated platforms: Chemistry (small molecules), Biotherapeutics (antibodies/proteins), xRNA (RNA therapeutics), Radioligand Therapy (targeted radiation), Gene Therapy, and Cell Therapy.
Pipeline
200| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Onasemnogene Abeparvovec-xioi | Spinal Muscular Atrophy 1 | Pre-clinical | |
| Lutetium-177 DOTATATE | Neuroendocrine Tumor | Pre-clinical | |
| Fingolimod | Multiple Sclerosis | Pre-clinical | |
| canakinumab | Cytokine Release Syndrome in COVID-19-induced Pneumonia | Pre-clinical | |
| Tacrolimus with MMF + Group 2: Tacrolimus with Everolimus. | End Stage Renal Failure With Renal Transplant | Pre-clinical |
FDA Approved Drugs
50
Company Timeline
Founded in Basel, Switzerland
FDA Approval: VIJOICE
FDA Approval: RHAPSIDO
FDA Approval: VANRAFIA